Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Otsuka's Sibeprenlimab?
Sibeprenlimab is a monoclonal antibody commercialized by Otsuka, with a leading Phase III program in IgA Nephropathy (Berger's Disease). According...
Data Insights
Sibeprenlimab by Visterra for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Sibeprenlimab is under clinical development by Visterra and currently in Phase III for IgA Nephropathy (Berger's Disease). According to GlobalData,...